UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

European journal of cancer (1990), 2016-12, Vol.69, p.S145-S145

2016

Volltextzugriff (PDF)

1571 Ideal Body Mass Index (BMI) is significantly different between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy

European journal of cancer (1990), 2015-09, Vol.51, p.S228-S228

2015

Volltextzugriff (PDF)

2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial

European journal of cancer (1990), 2015-09, Vol.51, p.S457-S457

2015

Volltextzugriff (PDF)

5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial

Annals of oncology, 2003-03, Vol.14 (3), p.395-399

2003

Volltextzugriff (PDF)

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

European journal of cancer (1990), 2015-09, Vol.51, p.S724-S724

2015

Volltextzugriff (PDF)

395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)

European journal of cancer (1990), 2014-11, Vol.50, p.126-127

2014

Volltextzugriff (PDF)

506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

European journal of cancer (1990), 2014-11, Vol.50, p.165-165

2014

Volltextzugriff (PDF)

476 Serum Proteomic Classification in Refractory Non-small-cell Lung Cancer Treated with Erlotinib +/− Pazopanib in a Randomized Placebo-controlled Phase II Study

European journal of cancer (1990), 2012-11, Vol.48, p.147-148

2012

Volltextzugriff (PDF)

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

European journal of cancer (1990), 2014-11, Vol.50, p.44-45

2014

Volltextzugriff (PDF)

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.189-189

2012

Volltextzugriff (PDF)

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

European journal of cancer (1990), 2012-11, Vol.48, p.188-188

2012

Volltextzugriff (PDF)

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Annals of oncology, 2016-12, Vol.27 (12), p.2268-2274

2016

Volltextzugriff (PDF)

Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

Annals of oncology, 2023-05, Vol.34 (5), p.498-499

2023

Volltextzugriff (PDF)

Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-11, Vol.25 (6), p.1123-1124

2022

Volltextzugriff (PDF)

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

Annals of oncology, 2023-01, Vol.34 (1), p.70-77

2023

Volltextzugriff (PDF)

Biological and predictive role of ERCC1 polymorphisms in cancer

Critical reviews in oncology/hematology, 2017-03, Vol.111, p.133-143

2017

Volltextzugriff (PDF)

Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-11, Vol.23 (6), p.1107-1108

2020

Volltextzugriff (PDF)

142P Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors

Annals of oncology, 2021-12, Vol.32, p.S1440-S1442

2021

Volltextzugriff (PDF)

Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)

Gynecologic oncology, 2019-06, Vol.154, p.11-12

2019

Volltextzugriff (PDF)

444 - A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

European journal of cancer (1990), 2016-12, Vol.69, p.S145-S145

2016

Volltextzugriff (PDF)

ERCC1 polymorphisms and oxaliplatin. A review of the literature and a monocentric experience in the absence of a ‘sliding doors’ trial

Critical reviews in oncology/hematology, 2017

2017

Volltextzugriff (PDF)

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.131-131

2009

Volltextzugriff (PDF)

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

European journal of cancer supplements, 2008, Vol.6 (12), p.19-19

2008

Volltextzugriff (PDF)

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

The Lancet (British edition), 2012-05, Vol.379 (9829), p.1893-1901

2012

Volltextzugriff (PDF)

Adjuvante Chemotherapie des kurativ resezierten Kolonkarzinoms

Verdauungskrankheiten, 2004-07, Vol.22 (7), p.208-215

2004

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(13)
Life Sciences & Biomedicine
(7)
Oncology
(7)
Science & Technology
(7)
Humans
(6)
Female
(3)
Metastases
(3)
Middle Aged
(3)
Abdominal Surgery
(2)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Biopsy
(2)
Cancer Research
(2)
Chemotherapy
(2)
Gastric Cancer
(2)
Gastroenterology
(2)
Gastroenterology & Hepatology
(2)
Letter To The Editor
(2)
Life Sciences
(2)
Male
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

1571 Ideal Body Mass Index (BMI) is significantly different between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy

2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial

5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)

506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

476 Serum Proteomic Classification in Refractory Non-small-cell Lung Cancer Treated with Erlotinib +/− Pazopanib in a Randomized Placebo-controlled Phase II Study

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna

Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

Biological and predictive role of ERCC1 polymorphisms in cancer

Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy

142P Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors

Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)

444 - A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

ERCC1 polymorphisms and oxaliplatin. A review of the literature and a monocentric experience in the absence of a ‘sliding doors’ trial

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

Adjuvante Chemotherapie des kurativ resezierten Kolonkarzinoms

Suchergebnisse filtern